BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2060 related articles for article (PubMed ID: 30312761)

  • 1. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
    Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
    Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
    Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
    J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
    Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
    EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
    Boulanger Piette A; Hamoudi D; Marcadet L; Kyomi Labelle F; Ovidiu David R; Bossé S; Argaw A; Frenette J
    PLoS One; 2018; 13(6):e0198408. PubMed ID: 29879154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
    Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
    PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of proteases in excitation-contraction coupling failure in muscular dystrophy.
    Mázala DA; Grange RW; Chin ER
    Am J Physiol Cell Physiol; 2015 Jan; 308(1):C33-40. PubMed ID: 25298424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.
    van Putten M; Hulsker M; Young C; Nadarajah VD; Heemskerk H; van der Weerd L; 't Hoen PA; van Ommen GJ; Aartsma-Rus AM
    FASEB J; 2013 Jun; 27(6):2484-95. PubMed ID: 23460734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydrobiopterin synthesis and metabolism is impaired in dystrophin-deficient mdx mice and humans.
    Lindsay A; Kemp B; Larson AA; Baumann CW; McCourt PM; Holm J; Karachunski P; Lowe DA; Ervasti JM
    Acta Physiol (Oxf); 2021 Apr; 231(4):e13627. PubMed ID: 33580591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle.
    Kennedy TL; Moir L; Hemming S; Edwards B; Squire S; Davies K; Guiraud S
    Skelet Muscle; 2017 Oct; 7(1):22. PubMed ID: 29065908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy.
    Bia BL; Cassidy PJ; Young ME; Rafael JA; Leighton B; Davies KE; Radda GK; Clarke K
    J Mol Cell Cardiol; 1999 Oct; 31(10):1857-62. PubMed ID: 10525423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.
    van Putten M; Kumar D; Hulsker M; Hoogaars WM; Plomp JJ; van Opstal A; van Iterson M; Admiraal P; van Ommen GJ; 't Hoen PA; Aartsma-Rus A
    Neuromuscul Disord; 2012 May; 22(5):406-17. PubMed ID: 22284942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial hydrogen sulfide supplementation improves health in the
    Ellwood RA; Hewitt JE; Torregrossa R; Philp AM; Hardee JP; Hughes S; van de Klashorst D; Gharahdaghi N; Anupom T; Slade L; Deane CS; Cooke M; Etheridge T; Piasecki M; Antebi A; Lynch GS; Philp A; Vanapalli SA; Whiteman M; Szewczyk NJ
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
    Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
    Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.